First Quarter 2026 Net Loss of $1,546,000 ($0.46 loss per share) v. Net Loss of $2,152,000 ($0.65 loss per share) in Prior Year Comparable Period First Quarter 2026 EBITDA, as adjusted, was a loss of $1,313,000 ($0.39 loss per share) v. loss of $1,949,000 ($0.59 loss per share) in Prior Year Comparable Period Backlog at March 31, 2026 was $13.2 million compared to $12.3 million at December 31, 2025 HAUPPAUGE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the first quarter ended March 31, 2026. First Quarter 2026 vs. First Quarter 2025Net sales were $5,245,000, as compared to $4,726,000. Gross margin was 23.3%, as compared to 12.4%. Net loss was $1,546,000 ($0.46 loss per share), as compared to a net loss of $2,152,000 ($0.65 loss per share). Earnings before...

 Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) — Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company...

LAS VEGAS, May 14, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal second quarter ended March 31, 2026.  Fiscal Second Quarter 2026 Key Highlights:Revenue was $102.9 million, compared to $107.0 million in the prior-year period Gross margin increased 80 basis points to 33.6%, compared to 32.8% in the prior-year period Operating loss was $2.0 million, compared to operating income of $2.1 million in the prior-year period.Excluding a non-cash goodwill impairment charge of approximately $4.0 million in the Steel Manufacturing segment, the fiscal second quarter 2026 operating income would have been approximately $2.0 millionNet loss was $2.4 million and diluted loss per share was $0.80, compared...

– Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 – – FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – – Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders – ALPHARETTA, Ga., May 14, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the first quarter ended March 31, 2026. “Dogwood is off to a strong operational start to 2026 driven by significant pipeline progress...

Delivers 900 Basis Point Gross Margin Expansion, Net Loss Cut 51% and $21 to $22 Million Annual Revenue Visibility Turnaround Momentum MCLEAN, Va., May 14, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leader in AI-driven cybersecurity and national security solutions with trusted relationships across the U.S. Government, numerous leading corporations, and high-profile individuals across all industries, announced today results for the first quarter ended March 31, 2026. “The first quarter of 2026 marks a clear inflection point in our transformation,” said Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “We nearly doubled gross margins, significantly reduced operating expenses and executed binding agreements to acquire Halo Privacy and...

—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update. “In the first quarter we continued to have productive discussions with potential strategic partners while releasing new data analyses that further extend our understanding...

Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025 Raises full-year 2026 IM8 revenue guidance to $190 million to $210 million (previously $180 million to $200 million) Company projects Q2 2026 revenue of $46 million to $48 million, with IM8 contributing $44 million to $46 million, representing approximately 33% sequential quarterly growth for IM8 IM8 announces the launch of 3 new SKUs in Q4 with Hydration, Creatine and Kids’ Gummies Prenetics divests full stake of digital assets for $41.3 million in proceeds, further boosting its cash balance Prenetics executed approximately $19 million of previously announced $40 million share buyback program Appointed consumer supplements finance veteran Brian J. Rosin as Chief Financial Officer of IM8 Company to...

N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026. “Our first quarter results reflect continued execution and the growing momentum of our functional beverage business,” said Jack Ross, CEO of Synergy CHC Corp. “During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate exceeding $4 million. With...

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)Strengthened balance sheet with $100 million financingLONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx...

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026. “Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment...